Wyss Institute's DoriVac combined vaccine and adjuvant technology uses nanoscale precision enabled by DNA origami to induce broad immunity against ...

By Bhanvi Satija Feb 27 (Reuters) - Europe's medicines regulator recommended approval for Moderna's COVID and flu combination vaccine on Friday, putting it on track to become the first single shot to ...

By Kamal Choudhury and Blake Brittain March 3 (Reuters) - Moderna has agreed to pay Genevant Sciences, a subsidiary of ...

The European Medicines Agency (EMA) announced Friday it has recommended Moderna’s combined mRNA COVID-19 and flu vaccine be ...

Meanwhile, Moderna is trying to reset its future around oncology.

Moderna has managed to eke out some temporary wins, paving the way for the homegrown biotech to focus on its next moves.

According to a study of more than 5.5 million adults aged 50 years or older, vaccination with the bivalent BA.1 mRNA booster ...

The US Food and Drug Administration has declined to review Moderna's approval application for its novel mRNA flu vaccine, causing a fall in the company's shares on late Tuesday. Moderna on Tuesday ...

The FDA refused last week to consider Moderna's application to sell a flu vaccine in 2026-2027. Today, the FDA changed its mind. The FDA had previously rejected Moderna's application, refusing even to ...

Moderna is up 51.1% since the beginning of the year, but at $46.62 per share, it is still trading 10.1% below its 52-week high of $51.87 from January 2026. Investors who bought $1,000 worth of Moderna ...

The U.S. Food and Drug Administration is refusing to consider Moderna’s application for a new flu vaccine made with Nobel Prize-winning mRNA technology, the company announced Tuesday.The news is the ...